Pharming Group (LTS:0QCO) Other Income (Expense) : €0.6 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Pharming Group Other Income (Expense)?

Pharming Group's other income expense for the Pharming Group's pretax income for the three months ended in Mar. 2025 was €0.1 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2025 was €0.6 Mil.

Pharming Group Other Income (Expense) Historical Data

The historical data trend for Pharming Group's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Other Income (Expense) Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

-22.08

9.03

9.92

11.66

0.25

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Income (Expense)	Get a 7-Day Free Trial															-0.18	5.56	0.32	-5.40	0.12

Pharming Group Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.6 Mil.

Pharming Group (LTS:0QCO) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (LTS:0QCO) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHGUF:USA PHARM:Netherlands PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines